Results 191 to 200 of about 50,819 (268)

Non-Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis. [PDF]

Muscle Nerve
Abi Aoun M, Beauvais D, Barnay M, Violleau MH, Mathis S, Duval F, Sole G.   +6 more
europepmc   +1 more source

Activation of Anergic B Cells During Development of Autoimmunity

Immunological Reviews, Volume 342, Issue 1, September 2026.
ABSTRACT In healthy individuals, autoreactive B cells are normally silenced via central and peripheral tolerance mechanisms. In the periphery, when autoreactive B cells recognize self‐antigen via their B cell receptor (BCR) (signal 1) but do not receive T cell help (signal 2), they undergo the tolerance mechanism called anergy.
Mohammad Mansoor, Brandon K. Hilliard, Mia J. Smith   +2 more
wiley   +1 more source

The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics. [PDF]

Front Immunol
Xue X, Liu C, Qiu C, Liu S, Liu F, Li Y.
europepmc   +1 more source

Cardiovascular Diseases and All‐Cause Mortality Risk in Patients With Prehypertension and Noncommunicable Diseases: Results From the Kailuan Study

The Journal of Clinical Hypertension, Volume 28, Issue 9, September 2026.
ABSTRACT It remains unclear whether prehypertension combined with noncommunicable diseases (NCDs) is associate with higher risks of cardiovascular diseases (CVD) and all‐cause mortality. The study aimed to investigate the associations of prehypertension with CVD and all‐cause mortality in individuals with or without NCDs.
Ruiying Zhang, Liuxin Li, Yanxiu Wang, Junjuan Li, Chunyu Ruan, Shouling Wu, Shuohua Chen, Renling Yang   +7 more
wiley   +1 more source

Efgartigimod-alfa therapy in acetylcholine receptor antibody myasthenia gravis: Romanian experience. [PDF]

Front Neurol
Grecu N, Mihalache OA, Davidescu EI, Bălașa R, Simu M, Văcăraș V, Vodă IM, Mușuroi AI, Ene AM, Petrescu DM, Mitu CE, Furnică L, Cornea A, Homorodean R, Vîlciu C, Tiu C.   +15 more
europepmc   +1 more source

Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis

Journal of the Peripheral Nervous System, Volume 31, Issue 3, September 2026.
ABSTRACT Background and Aims In ADHERE, subcutaneous efgartigimod PH20 (1000 mg once weekly) was effective and well tolerated in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). ADHERE+ is an open‐label extension of ADHERE assessing long‐term safety and efficacy. Methods Eligible participants from ADHERE run‐in period
Jeffrey A. Allen, Geoffrey Istas, Satoshi Kuwabara, Trevor Mole, Luis Querol, Simon Rinaldi, Mark Stettner, Benjamin Van Hoorick, Richard A. Lewis   +8 more
wiley   +1 more source

Age and Treatment Efficacy in Myasthenia Gravis: A Systematic Review, Meta-Analysis, and Meta-Regression. [PDF]

Eur J Neurol
Nelke C, Skrobol M, Theissen L, Sacca F, Ruck T.   +4 more
europepmc   +1 more source

Association Between Statin Initiation and Myasthenia Gravis Crisis. [PDF]

J Clin Neurol
Yoo WH, Noh Y, Kim SW, Shin HY, Shin JY, Lee H.   +5 more
europepmc   +1 more source

Prevalence and characteristics of patients with seronegative myasthenia gravis. [PDF]

J Neurol
Andersen RK, Ankjær P, Axelsen KH, Andersen LK, Vissing J, Witting N.   +5 more
europepmc   +1 more source

Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study. [PDF]

Front Immunol
Sun C, Liu D, Tang Y, Zhang B, Guo R, Gao T, Cao X, Hao S, Wang Q, Yu H, Chang T.   +10 more
europepmc   +1 more source